Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May;31(3):175-182.
doi: 10.1097/CCO.0000000000000520.

Targeting the androgen receptor and overcoming resistance in prostate cancer

David J Einstein  1 , Seiji Arai, Steven P Balk
Affiliations
Review

Targeting the androgen receptor and overcoming resistance in prostate cancer

David J Einstein et al. Curr Opin Oncol. 2019 May.

Abstract

Purpose of review: Prostate cancer (PCa) is diagnosed in one out of every nine men and is the second leading cause of cancer death among men. Although therapies targeting the androgen receptor (AR) are highly effective, development of resistance is universal and remains a major therapeutic challenge. Nonetheless, signaling via AR is frequently maintained despite standard androgen-signaling inhibition. We review the current understanding of mechanisms of resistance as well as therapeutic approaches to improving treatment of PCa via targeting of the AR.

Recent findings: Resistance to AR-targeting therapies may be mediated by several mechanisms, including amplification, mutation, and alternative splicing of AR; intratumoral androgen synthesis; activation of alternative signaling pathways; and in a minority of cases, emergence of AR-independent phenotypes. Recent trials demonstrate that intensification of androgen blockade in metastatic castration-sensitive PCa can significantly improve survival. Similar strategies are being explored in earlier disease states. In addition, several other cellular signaling pathways have been identified as mechanisms of resistance, offering opportunities for cotargeted therapy. Finally, immune-based approaches are in development to complement AR-targeted therapies.

Summary: Targeting the AR remains a critical focus in the treatment of PCa.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

Dr. Einstein is the PI of NCT03637543 and receives institutional research support from Bristol-Myers Squibb. Dr. Balk has consulted for Sanofi, Janssen, and Astellas.

Figures

Figure 1.
Figure 1.. Landscape of AR activity, RB1/TP53 activity, and neuroendocrine features in advanced PCa.
Each dot reflects hypothetical level of AR activity, RB1/TP53 activity, and neuroendocrine differentiation in an individual advanced tumor that is resistant to AR targeted therapies.
Figure 2.
Figure 2.
Standard and experimental approaches to target AR across the spectrum of PCa.
See this image and copyright information in PMC

References

    1. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–28. - PMC - PubMed
    1. Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018;50(5):645–51. - PMC - PubMed

    2. This study identified 70 new significantly mutated genes found at low prevalence in PCa and compared genomic markers in primary versus metastatic disease.

    1. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, et al. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018;174(3):758–69 e9. - PMC - PubMed

    2. This study identified amplification of an AR enhancer as a major mechanism driving increased AR expression in CRPC, and identifed an associatiin between CD12 loss and tandem duplications.

    1. Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, et al. Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precis Oncol. 2017;2017. - PMC - PubMed
    1. Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M, et al. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nat Genet. 2018;50(5):682–92. - PMC - PubMed

    2. This is a major sequencing effort that identified 22 novel putative driver genes harboring coding mutations, and it examined temporal genomic events in the progression of prostate cancer.

Publication types

MeSH terms